Literature DB >> 27614205

Transcriptome assessment of the Pompe (Gaa-/-) mouse spinal cord indicates widespread neuropathology.

S M F Turner1,2,3, D J Falk3,4,5, B J Byrne3,4,5, D D Fuller6,2,3.   

Abstract

Pompe disease, caused by deficiency of acid alpha-glucosidase (GAA), leads to widespread glycogen accumulation and profound neuromuscular impairments. There has been controversy, however, regarding the role of central nervous system pathology in Pompe motor dysfunction. We hypothesized that absence of GAA protein causes progressive activation of neuropathological signaling, including pathways associated with cell death. To test this hypothesis, genomic data (Affymetrix Mouse Gene Array 2.0ST) from the midcervical spinal cord in 6 and 16 mo old Pompe (Gaa-/-) mice were evaluated (Broad Institute Molecular Signature Database), along with spinal cord histology. The midcervical cord was selected because it contains phrenic motoneurons, and phrenic-diaphragm dysfunction is prominent in Pompe disease. Several clinically important themes for the neurologic etiology of Pompe disease emerged from this unbiased genomic assessment. First, pathways associated with cell death were strongly upregulated as Gaa-/- mice aged, and motoneuron apoptosis was histologically verified. Second, proinflammatory signaling was dramatically upregulated in the Gaa-/- spinal cord. Third, many signal transduction pathways in the Gaa-/- cervical cord were altered in a manner suggestive of impaired synaptic function. Notably, glutamatergic signaling pathways were downregulated, as were "synaptic plasticity pathways" including genes related to neuroplasticity. Fourth, many genes and pathways related to cellular metabolism are dysregulated. Collectively, the data unequivocally confirm that systemic absence of GAA induces a complex neuropathological cascade in the spinal cord. Most importantly, the results indicate that Pompe is a neurodegenerative condition, and this underscores the need for early therapeutic intervention capable of targeting the central nervous system.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  Pompe; cervical; neurodegeneration; neuroinflammation; plasticity

Mesh:

Substances:

Year:  2016        PMID: 27614205      PMCID: PMC6223572          DOI: 10.1152/physiolgenomics.00075.2016

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  51 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease.

Authors:  Sang Jin Kim; Kaviraja Udupa; Zhen Ni; Elena Moro; Carolyn Gunraj; Filomena Mazzella; Andres M Lozano; Mojgan Hodaie; Anthony E Lang; Robert Chen
Journal:  Neurology       Date:  2015-07-08       Impact factor: 9.910

3.  Altered sensory experience exacerbates stable dendritic spine and synapse loss in a mouse model of Huntington's disease.

Authors:  Reena Prity Murmu; Wen Li; Zsuzsanna Szepesi; Jia-Yi Li
Journal:  J Neurosci       Date:  2015-01-07       Impact factor: 6.167

4.  A description of the Molecular Signatures Database (MSigDB) Web site.

Authors:  Arthur Liberzon
Journal:  Methods Mol Biol       Date:  2014

5.  Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2.

Authors:  C Martini; G Ciana; A Benettoni; F Katouzian; G M Severini; R Bussani; B Bembi
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

6.  Diaphragm Pacing as a Rehabilitative Tool for Patients With Pompe Disease Who Are Ventilator-Dependent: Case Series.

Authors:  Barbara K Smith; David D Fuller; A Daniel Martin; Lawrence Lottenberg; Saleem Islam; Lee Ann Lawson; Raymond P Onders; Barry J Byrne
Journal:  Phys Ther       Date:  2016-02-18

7.  Altered activation of the diaphragm in late-onset Pompe disease.

Authors:  Barbara K Smith; Manuela Corti; A Daniel Martin; David D Fuller; Barry J Byrne
Journal:  Respir Physiol Neurobiol       Date:  2015-11-28       Impact factor: 1.931

8.  Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.

Authors:  Darin J Falk; Cathryn S Mah; Meghan S Soustek; Kun-Ze Lee; Mai K Elmallah; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

9.  Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice.

Authors:  Darin J Falk; Meghan S Soustek; Adrian Gary Todd; Cathryn S Mah; Denise A Cloutier; Jeffry S Kelley; Nathalie Clement; David D Fuller; Barry J Byrne
Journal:  Mol Ther Methods Clin Dev       Date:  2015-03-25       Impact factor: 6.698

10.  Quantitating the subtleties of microglial morphology with fractal analysis.

Authors:  Audrey Karperien; Helmut Ahammer; Herbert F Jelinek
Journal:  Front Cell Neurosci       Date:  2013-01-30       Impact factor: 5.505

View more
  13 in total

Review 1.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

3.  Impaired lysosomal acidification triggers iron deficiency and inflammation in vivo.

Authors:  King Faisal Yambire; Christine Rostosky; Takashi Watanabe; David Pacheu-Grau; Sylvia Torres-Odio; Angela Sanchez-Guerrero; Ola Senderovich; Esther G Meyron-Holtz; Ira Milosevic; Jens Frahm; A Phillip West; Nuno Raimundo
Journal:  Elife       Date:  2019-12-03       Impact factor: 8.140

Review 4.  Pharmacological modulation of hypoxia-induced respiratory neuroplasticity.

Authors:  Sara Turner; Kristi A Streeter; John Greer; Gordon S Mitchell; David D Fuller
Journal:  Respir Physiol Neurobiol       Date:  2017-11-29       Impact factor: 1.931

5.  Molecular and histologic outcomes following spinal cord injury in spiny mice, Acomys cahirinus.

Authors:  Kristi A Streeter; Michael D Sunshine; Jason O Brant; Aaron G W Sandoval; Malcolm Maden; David D Fuller
Journal:  J Comp Neurol       Date:  2019-12-19       Impact factor: 3.215

6.  Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease.

Authors:  J Hordeaux; L Dubreil; C Robveille; J Deniaud; Q Pascal; B Dequéant; J Pailloux; L Lagalice; M Ledevin; C Babarit; P Costiou; F Jamme; M Fusellier; Y Mallem; C Ciron; C Huchet; C Caillaud; M-A Colle
Journal:  Acta Neuropathol Commun       Date:  2017-09-06       Impact factor: 7.801

7.  Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.

Authors:  Pasqualina Colella; Pauline Sellier; Manuel J Gomez; Maria G Biferi; Guillaume Tanniou; Nicolas Guerchet; Mathilde Cohen-Tannoudji; Maryse Moya-Nilges; Laetitia van Wittenberghe; Natalie Daniele; Bernard Gjata; Jacomina Krijnse-Locker; Fanny Collaud; Marcelo Simon-Sola; Severine Charles; Umut Cagin; Federico Mingozzi
Journal:  EBioMedicine       Date:  2020-10-09       Impact factor: 8.143

Review 8.  The Respiratory Phenotype of Pompe Disease Mouse Models.

Authors:  Anna F Fusco; Angela L McCall; Justin S Dhindsa; Lucy Zheng; Aidan Bailey; Amanda F Kahn; Mai K ElMallah
Journal:  Int J Mol Sci       Date:  2020-03-24       Impact factor: 5.923

9.  Advancements in AAV-mediated Gene Therapy for Pompe Disease.

Authors:  S M Salabarria; J Nair; N Clement; B K Smith; N Raben; D D Fuller; B J Byrne; M Corti
Journal:  J Neuromuscul Dis       Date:  2020

10.  Ultrastructural and diffusion tensor imaging studies reveal axon abnormalities in Pompe disease mice.

Authors:  Ni-Chung Lee; Wei-Hao Peng; Li-Kai Tsai; Yen-Hsu Lu; Hao-Chun Wang; Yao-Chia Shih; Zeng-Xian Pung; Hsi-Yuan Hu; Wuh-Liang Hwu; Wen-Yih Isaac Tseng; Yin-Hsiu Chien
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.